Partial remission (PR) in type 1 diabetes (T1D) is accompanied by downregulation of the immune response. The CD8+ CD57+ T cells, termed effector memory cells, is expanded in several immune-mediated diseases, but their changes in the PR phase are unclear. Combined with flow cytometry and bioinformatics analysis, we found that CD8+ CD57+ T cells had strong cytotoxic functions and transcriptional heterogeneity, and that the proportion of CD8+ CD57+ T cells increased in new-onset patients, decreased in patients during PR and then repleted again after the end of PR. These findings suggests that CD8+ CD57+ T cells might have potential roles in immune modulation during the PR stage and might serve as a therapeutic target.

graphic
View largeDownload slide
graphic
View largeDownload slide
Disclosure

X.Li: None. T.Zhong: None. R.Tang: None. X.Li: None. L.Kang: None.

© 2023 by the American Diabetes Association
2023
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.